OptimizeRx Corp — Director's Dealing 2022

Jun 13, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2022-06-09

Reporting Person: Vos Ellen O'Connor (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-09	Restricted Stock Units	$	A	4637	Acquired		Common Stock (4637)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock.

F2: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders.